Clinical Trial

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) may stop the growth of tumor cells by allowing the immune system to attack the cancer. This phase II trial is studying how well TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) work in combination in treating patients with locally advanced or metastatic liver cancer.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2018-09-19; most recent amendment 2026-03-29.
Status change: Recruiting → Active, Not Recruiting 2024-10-10
Status change: Not Yet Recruiting → Recruiting 2019-11-06
Trial Details
NCT Number NCT03680508
Lead Sponsor University of Hawaii
Collaborators: GlaxoSmithKline
Conditions Adult Primary Liver Cancer, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Enrollment 42 participants
Start Date 2019-12-19
Primary Completion 2026-03-06 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-02